Loading
A phase 2 trial in pancreatic cancer, run by Herlev Hospital, not yet recruiting.
Molecularly Tailored Therapy in Advanced Pancreatic Cancer is a phase 2, randomised interventional study registered as NCT07802418 by Herlev Hospital, with a registry enrolment figure of 1200 participants, started 2026-10 and due to reach its primary completion in 2031-06. Interventions recorded: Arm 1: Molecularly Tailored Therapy; Arms 2: Standard-of-Care Therapy; Arm 3: Standard-of-Care Observational Cohort. Conditions listed: Pancreatic Cancer. Primary outcome: Progression-Free Survival in Randomized Participants. Sites: Denmark. No results are recorded here; the registry entry is the source.
Shares Pancreatic cancer trials open today (registry snapshot and UK sites), Metastatic pancreatic ductal adenocarcinoma and the tag pancreatic-deep-dive.
Shares Pancreatic cancer trials open today (registry snapshot and UK sites), Metastatic pancreatic ductal adenocarcinoma and the tag pancreatic-deep-dive.
Shares Pancreatic cancer trials open today (registry snapshot and UK sites), Metastatic pancreatic ductal adenocarcinoma and the tag pancreatic-deep-dive.
Shares Pancreatic cancer trials open today (registry snapshot and UK sites), Metastatic pancreatic ductal adenocarcinoma and the tag pancreatic-deep-dive.
Shares Pancreatic cancer trials open today (registry snapshot and UK sites), Metastatic pancreatic ductal adenocarcinoma and the tag pancreatic-deep-dive.
Shares Pancreatic cancer trials open today (registry snapshot and UK sites), Metastatic pancreatic ductal adenocarcinoma and the tag pancreatic-deep-dive.
Shares Pancreatic cancer trials open today (registry snapshot and UK sites), Metastatic pancreatic ductal adenocarcinoma and the tag pancreatic-deep-dive.
Shares Pancreatic cancer trials open today (registry snapshot and UK sites), Metastatic pancreatic ductal adenocarcinoma and the tag pancreatic-deep-dive.